Using Nanoliposomes to Make Cancer Therapies Safer and More Effective

Glioblastoma is an aggressive and rare brain cancer. Though it is typically treated with surgery, radiation, and chemotherapy, the prognosis for patients is grim with only 10 percent of surviving at least five years. Plus Therapeutics is developing a pipeline of radiotherapies that are encapsulated in nanoliposomes. Through novel deliver and formulation of these therapies, the company believes it can produce safer and more efficacious treatments. We spoke to Marc Hedrick, CEO of Plus Therapeutics, about the company’s nanoliposome technology, how it works, and why the company is focusing on rare cancers.